62348-22-5

Basic information

• Product Name: 4-Oxazolecarbonyl chloride, 2-methyl- (9CI)
• Synonyms: 4-Oxazolecarbonyl chloride, 2-methyl- (9CI);2-Methyl-1,3-oxazole-4-carbonyl chloride;2-methyl-4-oxazolecarbonyl chloride;2-methyloxazole-4-carbonyl chloride
• CAS NO: 62348-22-5
• Molecular Formula: C₅H₄ClNO₂
• Molecular Weight: 145.54376
• Product Categories: ACIDHALIDE
• Mol File: 62348-22-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Oxazolecarbonyl chloride, 2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Oxazolecarbonyl chloride, 2-methyl- (9CI)(62348-22-5)
• EPA Substance Registry System: 4-Oxazolecarbonyl chloride, 2-methyl- (9CI)(62348-22-5)

Safety Data

• Hazardous Substances Data: 62348-22-5(Hazardous Substances Data)

Upstream product

• 23012-17-1 2-methyl-1,3-oxazol-4-carboxylic acid 
• 10200-43-8 2-methyl-4-carbethoxy-1,3-oxazole 
• 85806-67-3 2-methyl-oxazole-4-carboxylic acid methyl ester 
• 61999-29-9 2-Methyl-4,5-dihydro-1,3-oxazole-4-carboxylic acid ethyl ester 

Downstream Products

• 100959-91-9 2-Methyloxazole-4-carboxamide 
• 301155-47-5 2''-Methyl-4-phenylselenyl-4,5-dihydro-2,4':2',4''-teroxazole-4-carboxylic acid methyl ester 
• 301155-42-0 2'-Methyl-4-phenylselenyl-4,5-dihydro-2,4'-bi(1,3-oxazoyl)-4-carboxylic acid methyl ester 
• 187269-86-9 2'-Methyl-2,4'-bi(1,3-oxazoyl)-4-carboxylic acid methyl ester 

Relevant articles and documents

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Towards New Tricyclic Motifs: Intramolecular C–H Arylation as the Key Step in a Formal [3+3] Cyclocondensation Strategy

Tricyclic scaffolds structurally related to the well-known benzodiazepine class of drugs show diverse biological activities strikingly different from those of their benzodiazepine counterparts. Interested by this scaffold-hopping perspective, we previousl

Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors

The invention provides a compound of formula (I) or a salt thereof: wherein R2 is H, C1-3alkyl, n-butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, —CN, or —CH2OH; R3 is inter alia optionally substituted C4-7cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); Ra is H, methyl or ethyl; Rb is H or methyl; R4 is H, methyl, ethyl, n-propyl, —C(O)-Me, or —C(O)—C1fluoroalkyl; and R5 is: —C(O)—(CH2)n—Ar, —C(O)-Het, —C(O)—C1-6alkyl, —C(O)—C1 fluoroalkyl, —C(O)—(CH2)2—C(O)—NR15bNR15b, —C(O)—CH2—C(O)—NR15bNR15b, —C(O)—NR15b—(CH2)m1—Ar, —C(O)—NR15b—Het, —C(O)—NR15b—C1-6alkyl, —C(O)—NR5aR5b, —S(O)2—(CH2)m2—Ar, —S(O)2-Het, —S(O)2—C1-6alkyl, or —CH2—Ar; or R4 and R5 taken together are —(CH2)p1—, —(CH2)2—X5—(CH2)2—, —C(O)—(CH2)p2—, —C(O)—N(R15)—(CH2)p3—; or NR4R5 is of sub-formula (y), (y1), (y2) or (y3). The invention provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as COPD and the like.